Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: T lymphocyte modulators - PanVera

Drug Profile

Research programme: T lymphocyte modulators - PanVera

Alternative Names: T lymphocyte modulators research programme - PanVera

Latest Information Update: 21 Oct 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PanVera LLC
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Immunosuppression

Most Recent Events

  • 21 Oct 2003 No development reported - Preclinical for Immunosuppression in USA (unspecified route)
  • 16 Apr 2003 PanVera LLC has been acquired by Invitrogen
  • 21 Aug 2002 Aurora Biosciences Corporation has merged with PanVera Corporation to form PanVera LLC
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top